@article {Pilotto2020.12.27.20248903, author = {Andrea Pilotto and Viviana Cristillo and Stefano Cotti Piccinelli and Nicola Zoppi and Giulio Bonzi and Davide Sattin and Silvia Schiavolin and Alberto Raggi and Antonio Canale and Stefano Gipponi and Ilenia Libri and Martina Frigerio and Michela Bezzi and Matilde Leonardi and Alessandro Padovani}, title = {Long-term neurological manifestations of COVID-19: prevalence and predictive factors}, elocation-id = {2020.12.27.20248903}, year = {2021}, doi = {10.1101/2020.12.27.20248903}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Clinical investigations have argued for long-term neurological manifestations in both hospitalized and non-hospitalized COVID-19 patients. It is unclear whether long-term neurological symptoms and features depend on COVID-19 severity.Methods from a sample of 208 consecutive non-neurological patients hospitalized for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardized clinical protocol. Prevalence and predictors of long-term neurological manifestations were evaluated using multivariate logistic regression analyses.Results At 6-month follow-up after hospitalisation due to COVID-19 disease, patients displayed a wide array of symptoms; fatigue (34\%), memory/attention (31\%), and sleep disorders (30\%) were the most frequent. At neurological examination, 40\% of patients exhibited neurological abnormalities, such as hyposmia (18.0\%), cognitive deficits (17.5\%), postural tremor (13.8\%) and subtle motor/sensory deficits (7.6\%). Older age, premorbid comorbidities and severity of COVID-19 were independent predictors of neurological manifestations in logistic regression analyses.Conclusions premorbid vulnerability and severity of SARS-CoV-2 infection impact on prevalence and severity of long-term neurological manifestations.Competing Interest StatementAndrea Pilotto served in the advisory board of Z-cube (technology division of Zambon pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Abbvie, Nutricia and Chiesi pharmaceuticals. He received research support from Vitaflo Germany and Zambon Italy. Viviana Cristillo has no financial conflicts to disclose. Stefano Cotti Piccinelli has no financial conflicts to disclose. Nicola Zoppi has no financial conflicts to disclose. Giulio Bonzi has no financial conflicts to disclose. Davide Sattin has no financial conflicts to disclose. Silvia Schiavolin has no financial conflicts to disclose. Alberto Raggi has no financial conflicts to disclose. Antonio Canale has no financial conflicts to disclose. Stefano Gipponi has no financial conflicts to disclose. Ilenia Libri has no financial conflicts to disclose. Martina Frigerio has no financial conflicts to disclose. Michela Bezzi has no financial conflicts to disclose. Matilde Leonardi has no financial conflicts to disclose. Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals. He is founded by Grant of Ministry of University (MURST). Funding StatementNo funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee of ASST Spedali Civili di Brescia Hospital and the requirement for informed consent was waived by the Ethics Commission (NP 4166).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/03/14/2020.12.27.20248903}, eprint = {https://www.medrxiv.org/content/early/2021/03/14/2020.12.27.20248903.full.pdf}, journal = {medRxiv} }